BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study

摘要: Malignant gliomas are rather refractory to current therapeutic approaches including surgery, radiotherapy, chemotherapy and immunotherapy. Acquired alterations in the pathways required for apoptotic cell death thought be responsible failure of glioma respond therapy. Here we have examined expression several proteins involved susceptibility apoptosis 20 human gliomas, BCL-2 family BCL-2, BCL-X, BAX MCL-1, as well p53 RB. Most expressed proteins. There was good correlation between functional antagonists, BCL-2/BCL-X BAX, suggesting that changes BCL-2+BCL-X/BAX ratio not differential response patients chemotherapy. The immunochemistry data were also analysed regard therapy clinical outcome. All had cytoreductive surgery received radiotherapy nitrosourea-based adjuvant no prominent association outcome with patterns p53, RB, BCL-X or BAX. We find, however, MCL-1 protein is associated early tumour recurrence shorter survival this group patients. This preliminary observation will confirmed a larger independent sample